Cases & Deals

Nuvalent establishes global patent portfolios for small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitors

Clients Nuvalent, Inc.

Jones Day represents Nuvalent, Inc. in the establishment and prosecution of global patent portfolios related to small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitors for the treatment of cancer.